B+
Bull case
25%
Probability
Target price
$68.39
+43.9% vs current
TEM
Tempus AIFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
55%
Probability
Target price
$44.12
-7.1% vs current
B-
Bear case
20%
Probability
Target price
$28.24
-40.6% vs current
AI sentiment snapshot
Latest data as of 2025-10-10
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+46.0
Score
AI commentary
Market sentiment is mixed-to-constructive: investors note meaningful long-term opportunity in AI-driven diagnostics but remain cautious on execution, margins, and near-term cash flow. Volatility typically spikes around earnings and regulatory updates.
RankAlpha Sentiment AI - 2025-10-10
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
-eventQuarterly earnings releaseHigh impact
Upcoming quarterly results and guidance are likely to reset consensus on revenue growth and margins and cause near-term share volatility.
-catalystCommercial partnerships and dataset expansionHigh impact
Securing major enterprise contracts or expanding datasets would validate revenue durability and support multiple expansion over 12–24 months.
Recommendation
N/A
No formal recommendation provided.
As of 2025-10-10 • Updated nightlySource: Internal modelMethodology